Clinical Trials Browser

Interventional × S 1 (combination) × 90 days × Clear all

NCT06256328 2026-03-13

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase 3 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05771480 2026-02-23

TOURMALINE

Phase 3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06519591 2026-02-18

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2 Active not recruiting

Adenocarcinoma

NCT06510010 2026-01-26

Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer

Phase 2 Recruiting

Chemotherapy Effect

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07038629 2026-01-07

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT03443492 2025-12-30

Pancreas

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Cancer Peritoneal Metastases